KRAS and pachyonychia congenita: Current progress was achieved through the phase I/II clinical trial, which revealed that the KRAS-G12C inhibitor sotorasib was associated with a 21.1% objective response rate and an 84.2% disease control rate among advanced PC patients who had already received at least one therapy for PC [42].